The objectives of this component of the program project grant are several fold: First the project will generate a library of HSV-2 deletion mutants, focusing primarily on several genes previously shown in HSV-1 genomes to affect the capacity of the virus to replicate in CNS tissues. This approach is dictated by the concern that HSV infection can result in encephalitis, with its attendant mortality and morbidity. Studies on HSV-1 have previously shown that deletion mutants incapable of replicating in the CNS of highly susceptible animals can be constructed. At the molecular level, the desirable mutants are those that are avirulent, yet produce vast amounts of virion structural proteins properly displayed on the surfaces of infected cells. Each mutant will be tested in Project 3 for its phenotypic behavior in mice. The second objective of the project is to insert appropriate HSV-1 glycoprotein genes into the suitable candidate vaccine strain(s) selected from the screens described above, in order to enhance immunity against HSV- 1 infection. A number of potential sites for insertion of the HSV-1 genes are available and will be tested. The third objective of this project is to screen the replicative capacity of the deletion mutants in a variety of cell lines and strains, but particularly in cells like the MRC-5 cell strain which has been licensed and approved for viral vaccine production. The fourth objective is to construct and test under appropriate promoters viruses carrying genes that express factors involved in enhancement of mucosal immunity. While such vaccines might well be construed to being in the category of the """"""""next generation"""""""", the currently evolving technology of tailoring promoters to required level of expression will be tested using genes specifying particular interleukins. In all of these projects, the design and ultimate structure of the vaccine candidate strains will take cognizance of and rest on the results of studies in Projects 2 and 3.

Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
1996
Total Cost
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
225410919
City
Chicago
State
IL
Country
United States
Zip Code
60637
Hellums, Elizabeth K; Markert, James M; Parker, Jacqueline N et al. (2005) Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol 7:213-24
Whitley, Richard J (2003) Smallpox: a potential agent of bioterrorism. Antiviral Res 57:7-12
Whitley, Richard J; Roizman, Bernard (2002) Herpes simplex viruses: is a vaccine tenable? J Clin Invest 110:145-51
Whitley, Richard J; Gnann, John W (2002) Viral encephalitis: familiar infections and emerging pathogens. Lancet 359:507-13
Markert, J M; Parker, J N; Gillespie, G Y et al. (2001) Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes 8:17-22
Parker, J N; Gillespie, G Y; Love, C E et al. (2000) Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A 97:2208-13
Markert, J M; Gillespie, G Y; Weichselbaum, R R et al. (2000) Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol 10:17-30
Tran, L C; Kissner, J M; Westerman, L E et al. (2000) A herpes simplex virus 1 recombinant lacking the glycoprotein G coding sequences is defective in entry through apical surfaces of polarized epithelial cells in culture and in vivo. Proc Natl Acad Sci U S A 97:1818-22
Kimberlin, D W; Whitley, R J (1998) Human herpesvirus-6: neurologic implications of a newly-described viral pathogen. J Neurovirol 4:474-85
He, B; Gross, M; Roizman, B (1998) The gamma134.5 protein of herpes simplex virus 1 has the structural and functional attributes of a protein phosphatase 1 regulatory subunit and is present in a high molecular weight complex with the enzyme in infected cells. J Biol Chem 273:20737-43

Showing the most recent 10 out of 42 publications